Dorzasopt (Eye Drops)
(Dorzolamide / Timolol)
Each ml contains dorzolamide 20 mg, timolol 54 mg.
- Increased intraocular pressure;
- Open-angled glaucoma (including pseudoexfoliative glaucoma and other types of
secondary open-angled glaucoma).
Hypersensibility to preparation components;
- Severe renal failure (CC less than 30 ml/mins);
- Hyperhloremic acidosis;
- Sinus bradycardia;
- AV-blockade of I and II degrees;
- Expressed heart failure;
- Cardiogenic shock;
- Dystrophic processes in cornea;
- Bronchial asthma (including the history);
- Severe obstructive lung disease;
- Severe allergic inflammation of nasal mucosa;
- Children and teenagers;
Generally the preparation is well tolerated. Inflammation of eyelid, irritation,
dryness, visual disturbances, allergic reactions are possible. Systemic adverse
effects are generally less expressed and do not lead to the preparation
DOSAGE AND ADMINISTRATION
1 drop of the preparation is instilled into conjunctival sac of an affected eye
2 times/day. While co-administrated with other ophthalmologic products interval
between instillation should be not less than 15 minutes.
PREGNANCY AND LACTATION
Administration in pregnancy is contraindicated. Breast-feeding should be stopped
during the treatment with the drug.
Eye drops contain preserving agent benzalkonium chloride therefore individuals
wearing hard contact lenses should remove them before instillation of a product
and wear again not less than in 15 minutes after instillation. One should not
wear soft contact lenses during treatment with the drug as preserving agent can
affect the eye.
5 ml in plastic vial with dropping stopper and screw cap, supplied with guard
ring. Vial in carton box with packaging leaflet.